The purpose of this study was to collect large volumes of matched pairs of pre- and post-vaccination sera from healthy subjects who administered GlaxoSmithKline (GSK) Biologicals' vaccine against meningitis- MenACWY vaccine (Menveo) or rMenB+OMV NZ vaccine (Bexsero), which serves for the development, qualification, validation, and maintenance of immunological assays which supports the preclinical research activities and clinical development of GSK Biologicals' vaccines. The safety of the subjects given one of the two vaccines (Bexsero or Menveo), as per the recommended dosage and schedule were assessed during their participation in the study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Human Blood Samples Collected for Conversion Into Serum at Day -83
Timeframe: At Day -83 [83 days before first vaccination (Day 1)]
Number of Human Blood Samples Collected for Conversion Into Serum at Day 8
Timeframe: At Day 8
Number of Human Blood Samples Collected for Conversion Into Serum at Day 98
Timeframe: At Day 98
Number of Human Blood Samples Collected for Conversion Into Serum at Day 151
Timeframe: At Day 151
Number of Human Blood Samples Collected for Conversion Into Serum at Day -60
Timeframe: At Day -60 [60 days before first vaccination (Day 1)]
Number of Human Blood Samples Collected for Conversion Into Serum at Day 31
Timeframe: At Day 31
Number of Human Blood Samples Collected for Conversion Into Serum at Day-30
Timeframe: At Day -30 [30 days before first vaccination (Day 1)]
Number of Human Blood Samples Collected for Conversion Into Serum at Day 61
Timeframe: At Day 61